**Chapter 15**

*New Insight into Cerebrovascular Diseases - An Updated Comprehensive Review*

[89] Temple R. Are surrogate markers adequate to assess cardiovascular disease drugs? Journal of the American Medical Association. 1999;**282**(8):790-795

[90] Adami D, Berkefeld J, Platz J, Konczalla J, Pfeilschifter W, Weidauer S, et al. Complication rate of intraarterial treatment of severe cerebral vasospasm

after subarachnoid hemorrhage with nimodipine and percutaneous transluminal balloon angioplasty: Worth the risk? Journal of Neuroradiology.

[91] Yao Z, Hu X, You C. Endovascular therapy for vasospasm secondary to subarachnoid hemorrhage: A meta-analysis and systematic review. Clinical Neurology and Neurosurgery.

[92] Cremers CH, Vos PC, van der Schaaf IC, Velthuis BK, Vergouwen MD, Rinkel GJ, et al. CT perfusion during delayed cerebral ischemia after subarachnoid hemorrhage: Distinction between reversible ischemia and ischemia progressing to infarction. Neuroradiology. 2015;**57**(9):897-902

[93] Dasa SSK, Suzuki R, Mugler E, Chen L, Jansson-Lofmark R, Michaelsson E, et al. Evaluation of pharmacokinetic and pharmacodynamic profiles of liposomes for the cell type-specific delivery of small molecule drugs. Nanomedicine.

2017;**13**(8):2565-2574

2019;**46**(1):15-24

2017;**163**:9-14

**256**
